CL2004000800A1 - COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS, REPLACED BY HETEROCICLES, PHARMACEUTICAL COMPOSITION, USEFUL AS A MODULATOR OF THE ACTIVATED RECEIVER OF PEROXISOMES PROPELLIFIER (PPAR-Y) TO TREAT DEPENDENT OR UNDERGROUND MELLITUS DIABETES, - Google Patents
COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS, REPLACED BY HETEROCICLES, PHARMACEUTICAL COMPOSITION, USEFUL AS A MODULATOR OF THE ACTIVATED RECEIVER OF PEROXISOMES PROPELLIFIER (PPAR-Y) TO TREAT DEPENDENT OR UNDERGROUND MELLITUS DIABETES,Info
- Publication number
- CL2004000800A1 CL2004000800A1 CL200400800A CL2004000800A CL2004000800A1 CL 2004000800 A1 CL2004000800 A1 CL 2004000800A1 CL 200400800 A CL200400800 A CL 200400800A CL 2004000800 A CL2004000800 A CL 2004000800A CL 2004000800 A1 CL2004000800 A1 CL 2004000800A1
- Authority
- CL
- Chile
- Prior art keywords
- propellifier
- heterocicles
- peroxisomes
- ppar
- underground
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46321303P | 2003-04-15 | 2003-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004000800A1 true CL2004000800A1 (en) | 2005-03-04 |
Family
ID=33300053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200400800A CL2004000800A1 (en) | 2003-04-15 | 2004-04-14 | COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS, REPLACED BY HETEROCICLES, PHARMACEUTICAL COMPOSITION, USEFUL AS A MODULATOR OF THE ACTIVATED RECEIVER OF PEROXISOMES PROPELLIFIER (PPAR-Y) TO TREAT DEPENDENT OR UNDERGROUND MELLITUS DIABETES, |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1615899A1 (en) |
JP (1) | JP2006523671A (en) |
KR (1) | KR20060009846A (en) |
CN (1) | CN1805943A (en) |
AP (1) | AP2005003418A0 (en) |
AR (1) | AR044514A1 (en) |
AU (1) | AU2004230316A1 (en) |
BR (1) | BRPI0409429A (en) |
CA (1) | CA2521915A1 (en) |
CL (1) | CL2004000800A1 (en) |
EA (1) | EA200501462A1 (en) |
EC (1) | ECSP056105A (en) |
IS (1) | IS8033A (en) |
MA (1) | MA27764A1 (en) |
MX (1) | MXPA05010967A (en) |
NL (1) | NL1025946C2 (en) |
NO (1) | NO20055370L (en) |
OA (1) | OA13157A (en) |
PA (1) | PA8600201A1 (en) |
PE (1) | PE20050415A1 (en) |
TN (1) | TNSN05262A1 (en) |
TW (1) | TW200510353A (en) |
UY (1) | UY28266A1 (en) |
WO (1) | WO2004092145A1 (en) |
ZA (1) | ZA200508362B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008500357A (en) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Substituted triazoles as modulators of PPARs and methods for their preparation |
NZ563866A (en) | 2005-05-09 | 2011-03-31 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
JP5043120B2 (en) | 2006-10-30 | 2012-10-10 | クロマ セラピューティクス リミテッド | Hydroxamates as inhibitors of histone deacetylase |
US20110021534A1 (en) * | 2007-03-08 | 2011-01-27 | Albireo Ab | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
CA2687817A1 (en) | 2007-05-22 | 2008-12-04 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
CA2729965A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
BRPI0916713A2 (en) | 2008-07-28 | 2015-11-10 | Gilead Science Inc | cycloalkylidene and heterocycloalkylidene histone deacetylase inhibiting compounds |
CA2763167A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
BRPI1010884A2 (en) | 2009-06-08 | 2016-03-15 | Gilead Sciences Inc | hdac alkanoylamino benzamide aniline inhibitors compound |
DE102010055499A1 (en) * | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Preparing bendamustine alkyl ester compounds, comprises reacting substituted 2-((2-hydroxy-ethyl)-phenyl-amino)-ethanol compounds with a mixture comprising carbonyl amine compounds and sulfonyl compounds, or diketo compounds |
BR112014010368A2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaryl ether sulfonamides and their use as therapeutic agents |
US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
FR2982858B1 (en) * | 2011-11-18 | 2013-11-29 | Rhodia Operations | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS |
FR2984322B1 (en) * | 2011-12-16 | 2013-12-20 | Rhodia Operations | PROCESS FOR PRODUCING COMPOUNDS COMPRISING NITRIL FUNCTIONS |
US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
BR112015000187A2 (en) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamides substituted with n and methods of use thereof |
JP6096370B2 (en) | 2013-03-14 | 2017-03-15 | ジェネンテック, インコーポレイテッド | Substituted triazolopyridines and methods of use |
CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
EA201691085A1 (en) | 2013-11-27 | 2017-02-28 | Дженентек, Инк. | SUBSTITUTED BENZAMIDES AND METHODS OF THEIR APPLICATION |
EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
WO2016191312A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
CN108495851A (en) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | Substituted benzamide and its application method |
JP2019513714A (en) | 2016-03-30 | 2019-05-30 | ジェネンテック, インコーポレイテッド | Substituted benzamides and methods of use thereof |
PE20190980A1 (en) | 2016-10-17 | 2019-07-09 | Genentech Inc | THERAPEUTIC COMPOUNDS AND METHODS TO USE THEM |
EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
TW202000651A (en) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | Therapeutic compounds and methods of use thereof |
EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1088824B1 (en) * | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
JP2004520397A (en) * | 2001-02-15 | 2004-07-08 | ファイザー・プロダクツ・インク | Proliferative activator receptor (PPAR) compounds |
-
2004
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Application Discontinuation
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/en active Pending
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/en not_active Application Discontinuation
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/en unknown
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/en not_active IP Right Cessation
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/en not_active Application Discontinuation
- 2004-04-01 EA EA200501462A patent/EA200501462A1/en unknown
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/en active Pending
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/en not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/en unknown
- 2004-04-13 UY UY28266A patent/UY28266A1/en not_active Application Discontinuation
- 2004-04-14 NL NL1025946A patent/NL1025946C2/en not_active IP Right Cessation
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/en unknown
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/en unknown
- 2004-04-14 TW TW093110410A patent/TW200510353A/en unknown
-
2005
- 2005-09-15 IS IS8033A patent/IS8033A/en unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/en unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/en unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/en unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY28266A1 (en) | 2004-11-30 |
WO2004092145A8 (en) | 2005-05-12 |
WO2004092145A1 (en) | 2004-10-28 |
CN1805943A (en) | 2006-07-19 |
NL1025946C2 (en) | 2005-02-01 |
EA200501462A1 (en) | 2006-04-28 |
TW200510353A (en) | 2005-03-16 |
NO20055370L (en) | 2006-01-12 |
AP2005003418A0 (en) | 2005-12-31 |
JP2006523671A (en) | 2006-10-19 |
OA13157A (en) | 2006-12-13 |
IS8033A (en) | 2005-09-15 |
ZA200508362B (en) | 2006-11-29 |
NO20055370D0 (en) | 2005-11-14 |
CA2521915A1 (en) | 2004-10-28 |
ECSP056105A (en) | 2006-03-01 |
AU2004230316A1 (en) | 2004-10-28 |
TNSN05262A1 (en) | 2007-07-10 |
AR044514A1 (en) | 2005-09-14 |
PA8600201A1 (en) | 2005-02-04 |
MXPA05010967A (en) | 2005-11-28 |
KR20060009846A (en) | 2006-02-01 |
BRPI0409429A (en) | 2006-04-18 |
NL1025946A1 (en) | 2004-10-18 |
MA27764A1 (en) | 2006-02-01 |
EP1615899A1 (en) | 2006-01-18 |
PE20050415A1 (en) | 2005-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004000800A1 (en) | COMPOUNDS DERIVED FROM CARBOXYLIC ACIDS, REPLACED BY HETEROCICLES, PHARMACEUTICAL COMPOSITION, USEFUL AS A MODULATOR OF THE ACTIVATED RECEIVER OF PEROXISOMES PROPELLIFIER (PPAR-Y) TO TREAT DEPENDENT OR UNDERGROUND MELLITUS DIABETES, | |
CL2007002348A1 (en) | HETEROCICLICAL COMPOUNDS, MODULATORS OF THE ACTIVITY OF ESTEAROIL-COA-DESATURASA; PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF DISEASES SUCH AS DIABETES, DISLIPIDEMIAS, OBESITY, ANOREXIA AND ACNE. | |
WO2009054390A1 (en) | Thiazolidinedione compound | |
CL2007003854A1 (en) | COMPOUNDS DERIVED FROM CYCLOPAMINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND, USEFUL IN THE TREATMENT OF DISORDERS MEDIATED BY THE HEDGEHOG ROAD, AS CANCER. | |
WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
CL2007002841A1 (en) | COMPOUNDS DERIVED FROM INDOL, ANTIGONISTS OF THE GLUCAGION RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT MELLITUS TYPE 2 DIABETES, HYPERGLUCEMIA, DIABETES OR INSULIN RESISTANCE. | |
CL2007003049A1 (en) | COMPOUNDS DERIVED FROM 2,4-DIAMINOPIRIMIDINE; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT PROLIFERATIVE DISORDERS. | |
CL2007001885A1 (en) | Compounds derived from tropane urea, modulators of the activity of 11betahsd1; preparation procedure; pharmaceutical composition; and use for the treatment of diseases such as obesity, diabetes, hypertension, atherosclerosis, dementia and osteoporosis. | |
CL2009000889A1 (en) | Compounds derived from 2-oxo-2,5-dihydro pyrrole propionamide, glucokinase activators; preparation procedure; pharmaceutical composition comprising said compounds; and its use in the treatment of diabetes mellitus. | |
WO2008001931A3 (en) | Fused cyclic compounds | |
CL2007002197A1 (en) | COMPOUNDS DERIVED FROM INDOL; PREPARATION PROCEDURE; INTERMEDIARY COMPOUND; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF MELLITUS DIABETES, DIABETIC RETINOPATHY, HYPERGLUCEMIA, HYPERL | |
CL2008002110A1 (en) | PROCEDURE FOR THE MODULATION OF THE RECEPTOR COUPLED TO PROTEIN G GPR119 TO ADMINISTER A COMPOUND DERIVED FROM PIRIDINONE AND OPTIONALLY AN OPTIONAL THERAPEUTIC AGENT TO TREAT MELLITUS DIABETES. | |
EA201170304A1 (en) | GLUOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES | |
DK2209778T3 (en) | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
WO2007025613A3 (en) | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | |
EA201170302A1 (en) | PROCESSED ANALOGUES OF GLUEL-DEPENDENT INSULINOTROPIC POLYPETIDE | |
CL2008001049A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED BENZAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DIABETES, INTOLERANCE TO GLUCOSE, DISLIPIDEMIA, HYPERTENSION, OBESITY. | |
CL2011000478A1 (en) | Compounds derived from substituted 2-imidazol-propanamide, glucokinase activators; Pharmaceutical composition, useful for treating or delaying the progression or onset of type II diabetes or diabetes-related disorders. | |
CY1112483T1 (en) | Piperidine GPCR agonists | |
WO2007003962A3 (en) | Gpcr agonists | |
ATE555105T1 (en) | HETEROCYCLIC FXR BINDING COMPOUNDS | |
BRPI0909768A2 (en) | compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by activation of b3-adrenoceptor, and use of a compound, pharmaceutical composition, method for treating or preventing a disease or disorder mediated by b3-adrenoceptor. b3-adrenoceptor activation, and use of a compound | |
MX2012003389A (en) | Pyrrolidine gpr40 modulators. | |
CL2009001595A1 (en) | Amorphous and crystalline form of (2s, 3r, 4r, 5s, 6r) -2- (4-chloro-3- (4-ethoxybenzyl) phenyl) -6- (methylthio) tetrahydro-2h-pyran-3,4,5 -anhydrous triol; Pharmaceutical composition comprising the crystalline form, useful to reduce blood glucose, restore insulin sensitivity, treat type 2 diabetes. Obesity. | |
GT200600453A (en) | ACILO INDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCEDURES OF USE |